Related Experiment Video

Updated: Jul 4, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Insulin pump therapy in children and adolescents with type 1 diabetes: the Italian viewpoint

Leonardo Pinelli1, Ivana Rabbone, Silvana Salardi

  • 1Childhood Diabetes Unit, University of Verona, Italy. l.pinelli@univr.it

Acta Bio-Medica : Atenei Parmensis
|June 17, 2008
PubMed

Insights

Italian experts adapted international insulin pump therapy guidelines for children with type 1 diabetes, considering local factors and legal requirements for safe and effective treatment.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Management
  • Medical Guidelines

Background:

  • International recommendations for insulin pump therapy in pediatric type 1 diabetes were reviewed.
  • Adaptation of guidelines for the Italian context was necessary.

Purpose of the Study:

  • To translate and adapt international insulin pump therapy recommendations for Italian children and adolescents with type 1 diabetes.
  • To ensure guidelines are contextually relevant and legally compliant.

Main Methods:

  • Literature review and evidence-based recommendations.
  • Evaluation of patient selection, therapy planning, device choice, and follow-up.
  • Cost-effectiveness analysis of insulin pump therapy versus multiple daily injections.

Main Results:

  • Adaptations were made for Italian diet, lifestyle, and legal framework.
  • Specific considerations for neonatal diabetes and an "informed therapeutic agreement" were introduced.
  • Guidelines address various scenarios including sick days, travel, and exercise.

Conclusions:

  • Clinical guidelines require faithful adaptation to local languages and contexts.
  • International collaboration in developing localized guidelines is crucial for effective diabetes management.
  • Adherence to specific national legal and cultural particularities enhances guideline utility.
Abstract

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...